Placental drug disposition and its clinical implications

被引:0
|
作者
Weier, Naomi [2 ]
He, Shu-Ming [1 ]
Li, Xiao-Tian [3 ]
Wang, Lin-Lin [4 ,5 ]
Zhou, Shu-Feng [4 ]
机构
[1] Xiaolan Peoples Hosp, Dept Obstet & Genecol, Zhongshan, Guangdong, Peoples R China
[2] Queensland Univ Technol, Sch Life Sci, Div Pharma, Brisbane, Qld, Australia
[3] Fudan Univ, Obstet & Gynecol Hosp, Dept Maternal Med, Shanghai 200433, Peoples R China
[4] RMIT Univ, WHO Collaborating Ctr Tradit Med, Sch Hlth Sci, Div Chinese Med, Melbourne, Vic, Australia
[5] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100083, Peoples R China
关键词
placenta; drug metabolism; drug transporter; cytochrome P450; P-glycoprotein;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The placenta is a unique organ that is essential to a healthy and normal pregnancy. A number of phase I and II metabolizing enzymes are expressed at moderate levels in the placenta, and have been proven to have the ability to metabolize certain xenobiotics. Depending on the substrate, this metabolic action may have significant clinical implications on how it affects the fetus. A wide variety of transporters including P-glycoprotein, breast cancer resistance protein, and multidrug resistance associated proteins have also been discovered in the placenta, and while most are found to have mainly physiological substrates, there are a number of xenobiotics which are also able to gain access to the fetus through transport across the placenta. Depending on the xenobiotics and its intended action, drug transport across the placenta may be desired, acceptable or undesirable. Medications administered to the mother but designed to work on the fetus are now being used increasingly, and demonstrates an important clinical implication in which drug transport across the placenta is desirable. However, medications designed to treat the mother but are also able to cross the placenta carry potential risks to damage the developing fetus, and it is therefore essential that the effects of different drugs on the fetus are known before they are administered during pregnancy. There is still much unknown about drug transport and drug metabolism in the placenta, and it is vital that in the future further research is done to discover the clinical implications of these activities in the placenta. This research is often complicated by the fact that it is unethical to run studies in pregnant women, and so research is often carried out in pregnant animals. These results are not always accurate, however, as the human's placental structure is different from the placenta in other animals. Drug metabolism and drug transport across the placenta should continue to be researched, and guidelines need to be developed to ensure that any medications used during pregnancy are safe to both the mother and the fetus, and that successful treatment of the medical condition is carried out.
引用
收藏
页码:106 / 121
页数:16
相关论文
共 50 条
  • [1] Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications
    Tomson, Torbjorn
    Landmark, Cecilie Johannessen
    Battino, Dina
    EPILEPSIA, 2013, 54 (03) : 405 - 414
  • [3] Overview: Role of Drug Transporters in Drug Disposition and Its Clinical Significance
    Liu, Xiaodong
    DRUG TRANSPORTERS IN DRUG DISPOSITION, EFFECTS AND TOXICITY, 2019, 1141 : 1 - 12
  • [4] Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
    Gharavi, Robert
    Hedrich, William
    Wang, Hongbing
    Hassan, Hazem E.
    PHARMACEUTICAL RESEARCH, 2015, 32 (08) : 2477 - 2502
  • [5] Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
    Robert Gharavi
    William Hedrich
    Hongbing Wang
    Hazem E. Hassan
    Pharmaceutical Research, 2015, 32 : 2477 - 2502
  • [6] Transporters and drug therapy: Implications for drug disposition and disease
    Ho, RH
    Kim, RB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) : 260 - 277
  • [7] DRUG ANALYSIS IN SAMPLES AND ITS CLINICAL IMPLICATIONS
    UEMATSU, T
    ASIA PACIFIC JOURNAL OF PHARMACOLOGY, 1994, 9 (01): : 43 - 48
  • [8] PLACENTAL-TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN NEWBORN
    MANDELLI, M
    MORSELLI, PL
    NORDIO, S
    PARDI, G
    PRINCIPI, N
    SERENI, F
    TOGNONI, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1975, 17 (05) : 564 - 572
  • [9] DRUG DISPOSITION AND PHARMACOKINETICS IN THE MATERNAL-PLACENTAL-FETAL UNIT
    KRAUER, B
    KRAUER, F
    HYTTEN, FE
    PHARMACOLOGY & THERAPEUTICS, 1980, 10 (02) : 301 - 328
  • [10] Reproductive placental corticotropin-releasing hormone and its clinical implications
    Chrousos, GP
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (01) : S249 - S250